CLARITYNE

This brand name is authorized in Austria, Cyprus, Ecuador, France, Hong Kong SAR China, Malta, Mexico, Nigeria, Singapore, South Africa, Spain.

Active ingredients

The drug CLARITYNE contains one active pharmaceutical ingredient (API):

1	Loratadine UNII 7AJO3BO7QN - LORATADINE
	Loratadine is a tricyclic antihistamine with selective, peripheral H1-receptor activity. Loratadine has no clinically significant sedative or anticholinergic properties in the majority of the population and when used at the recommended dosage.
	Read more about Loratadine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CLARITYNE Syrup / Tablet	MPI, Generic	Health Products Regulatory Authority (ZA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R06AX13	Loratadine	R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AX Other antihistamines for systemic use
Discover more medicines within R06AX13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	364300213
ES	Centro de información online de medicamentos de la AEMPS	58518
FR	Base de données publique des médicaments	67040450
HK	Department of Health Drug Office	30504, 37263, 66827
MT	Medicines Authority	PI1438/09601A
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	001M89, 045M88, 309M94
NG	Registered Drug Product Database	04-2471
Switch country to Nigeria in order to find specific presentations of CLARITYNE
SG	Health Sciences Authority	08022P, 14077P
ZA	Health Products Regulatory Authority	30/5.7.1/0493, 31/5.7.1/0509, U/5.7.1/27, Z/5.7.1/56